Abstract:Colorectal liver metastasis (CLM) is common worldwide. Targeted therapies with monoclonal antibodies have been proven effective in numerous clinical trials, and are now becoming standards for patients with CLM. The development and application of anti-epidermal growth factor receptor (anti-EGFR) and anti-vascular endothelial growth factor (anti-VEGF) antibodies represents significant advances in the treatment of this disease. However, new findings continue to emerge casting doubt on the efficacy of this approach. The Kirsten rat sarcoma viral oncogene (KRAS) has been proven to be a crucial predictor of the success of anti-EGFR treatment in CLM. Whereas a recent study summarized several randomized controlled trials, and showed that patients with the KRAS G13D mutation significantly benefited from the addition of cetuximab in terms of progress-free survival (PFS, 4.0 mo vs 1.9 mo, HR = 0.51, P = 0.004) and overall survival (OS, 7.6 mo vs 5.7 mo, HR = 0.50, P = 0.005). Some other studies also reported that the KRAS G13D mutation might not be absolutely predictive of non-responsiveness to anti-EGFR therapy. At the same time, "new" RAS mutations, including mutations in neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) and exons 3 and 4 of KRAS, have been suggested to be predictors of a poor treatment response. This finding was first reported by the update of the PRIME trial. The update showed that for patients with non-mutated KRAS exon 2 but other RAS mutations, panitumumab-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) 4 treatment led to inferior PFS (HR = 1.28, 95% CI: 0.79-2.07) and OS (HR = 1.29, 95% CI: 0.79-2.10), which was consistent with the findings in patients with KRAS mutations in exon 2. Then, the update of the PEAK trial and the FIRE-III trial also supported this finding, which would reduce candidates for anti-EGFR therapy but enhance the efficacy. In first-line targeted combination therapy, the regimens of cetuximab plus FOLFOX was called into question because of the inferior prognosis in the COIN trial and the NORDIC-IV trial. Also, bevacizumab plus oxaliplatin-based chemotherapy was questioned because of the NO16966 trial. By the update and further analysis of the COIN trial and the NORDIC-VII trial, cetuximab plus FOLFOX was reported to be reliable again. But bevacizumab plus oxaliplatin-based chemotherapy was still controversial. In addition, some trials have reported that bevacizumab is not suitable for conversion therapy. The results of the FIRE-III trial showed that cetuximab led to a significant advantage over bevacizumab in response rate (72% vs 63%, P = 0.017) for evaluable population. With the balanced allocation of second-line treatment, the FIRE. trial was expected to provide evidence for selecting following regimens after first-line progression. There is still no strong evidence for the efficacy of targeted therapy as a preoperative treatment for resectable CLM or postoperative treatment for resected CLM, although the combined regimen is often administered based on experience. Combination therapy with more than one targeted agent has been proven to provide no benefit, and even was reported to be harmful as first-line treatment by four large clinical trials. However, recent studies reported positive results of erlotinib plus bevacizumab for maintenance treatment. The mechanism of antagonism between different targeted agents deserves further study, and may also provide greater understanding of the development of resistance to targeted agents. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Should Anti-Egfr Mabs Be Discontinued for Conversion Surgery in Untreated Right-Sided Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis.

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

Efficacy of conversion therapy on future liver remnant hypertrophy for initially unresectable colorectal liver metastases: a review of current status and perspectives

The Optimal First-Line Treatment for Patients with Left-Sided RAS Wild-Type Metastatic Colorectal Cancer: Double-drug Regimen or Triple-Drug Regimen Therapy

Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.

Patients with RAS Wild-Type Right-Sided Unresectable Liver-Confined Mcrc Also Benefit from Cetuximab Plus Chemotherapy in First-Line Treatment

FOLFOX Plus Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody (mab) is an Effective First-Line Treatment for Patients with RAS-wild Left-Sided Metastatic Colorectal Cancer

Abstract 5531: PD-1 blockades plus targeted therapy and cytotoxic drugs as conversion therapy in unresectable metastatic colorectal cancer (mCRC): A real-world experience

Conversion therapy for liver metastases of colorectal cancer

Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study

The Role of Cetuximab in Converting Initially Unresectable Colorectal Cancer Liver Metastases for Resection.

Right- and Left-Sided Colorectal Cancers Respond Differently to Cetuximab

Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.

Phase II APEC Trial: the Impact of Primary Tumor Side on Outcomes of First‐line Cetuximab Plus FOLFOX or FOLFIRI in Patients with RAS Wild‐type Metastatic Colorectal Cancer

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF -mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI ☆

Anatomical Resection Improves Relapse-Free Survival in Colorectal Liver Metastases in Patients with KRAS/NRAS/BRAF Mutations or Right-Sided Colon Cancer: a Retrospective Cohort Study.

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes

Explanatory role of conversion surgery as a mediator of the mortality risk difference between patients with unresectable metastatic colorectal cancer treated with first-line anti-EGFR agents versus bevacizumab

Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation: A Multicenter Real-World Study in China.

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy

Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients with KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases.